ALBIREO PHARMA,INC. (NASDAQ:ALBO) Files An 8-K Entry into a Material Definitive Agreement
Item 2.03 Entry into a Material Definitive Agreement.

On March28, 2019, Albireo Pharma,Inc. (the “Company”) entered into an amendment to the Office Lease Agreement dated February7, 2017 with SHIGO 10 PO Owner LLC (the “Landlord”) to (i)replace the existing office space with a new office space measuring approximately 14,734 rentable square feet (the “Replacement Office”) and (ii)extend the term of the lease through the date ending eighty-eight (88) months after the date upon which the Landlord will have substantially completed the work necessary to deliver the Replacement Office in accordance with the agreed upon Scope of Work and Concept Plan. The Replacement Office is in the building located at 10 Post Office Square, Boston, Massachusetts and will serve as the Company’s executive offices.

The Company will be obligated to make monthly rent payments in an amount beginning at $72,442.17, at an annual rate of $59.00 per rentable square foot increasing by $1.00 annually for the term of the lease.

The foregoing summary of the lease amendment is qualified in its entirety by reference to the full text of the lease amendment, a copy of which is attached as Exhibit10.1 to this Current Report on Form8-K and incorporated herein by reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The disclosure set forth above under Item 2.03 is incorporated herein by reference.

Item 2.03 Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is furnished with this report: